Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naive patients: a Phase 2 "proxy" study

被引：0
|
作者：
Gane, Edward J. [1 ]
Kocinsky, Hetal [2 ]
Schwabe, Christian [3 ]
Mader, Michael [2 ]
Suri, Vithika [3 ]
Donohue, Mary K. [2 ]
Huang, Mingjun [2 ]
Hui, James [2 ]
Yang, Joanna [2 ]
Apelian, David [2 ]
机构：
[1] Auckland Hosp, New Zealand Liver Transplant Unit, Auckland, New Zealand
[2] Achill Pharmaceut, New Haven, CT USA
[3] Auckland Clin Studies Ltd, Grafton, New Zealand
来源：
HEPATOLOGY | 2014年 / 60卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LB-23
引用
收藏
页码：1281A / 1282A
页数：2
相关论文
共 50 条
  • [1] SUSTAINED VIROLOGIC RESPONSE AFTER ACH-3102 AND SOFOSBUVIR TREATMENT FOR 8 OR 6 WEEKS: A PHASE 2 "PROXY" STUDY
    Gane, E.
    Schwabe, C.
    Mader, M.
    Suri, V.
    Donohue, M.
    Huang, M.
    Hui, J.
    Yang, J.
    Robison, H.
    Apelian, D.
    Kocinsky, H.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S266 - S266
  • [2] ACHIEVEMENT OF SVR12 DESPITE THE PRESENCE OF HCV VARIANTS RESISTANT TO FIRST GENERATION NS5A INHIBITORS IN GENOTYPE-1 HEPATITIS C PATIENTS AFTER 8-WEEK THERAPY OF ACH-3102 IN COMBINATION WITH SOFOSBUVIR
    Patel, D.
    Zhao, Y.
    Fabrycki, J.
    Yang, G.
    Podos, S.
    Kocinsk, H.
    Mader, M.
    Gane, E.
    Schwabe, C.
    Apelian, D.
    Huang, M.
    Yang, W.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S636 - S636
  • [3] LOW SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN GENOTYPE (GT) 2 AND 3 PATIENTS WITH QUANTIFIABLE HEPATITIS C VIRUS (HCV) AT WEEK 4 OF TREATMENT WITH SOFOSBUVIR (SOF) CONTAINING REGIMENS
    Thornton, K.
    Deming, P.
    Sedillo, M.
    Qualls, C.
    Box, T.
    Scott, J.
    Cox, P.
    Mera, J.
    Miller, A.
    Manch, R.
    Kohli, A.
    Gish, R.
    Moore, A.
    Sussman, N.
    Khaderi, S.
    Arora, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S786 - S786
  • [4] ADDITIONAL BOCEPREVIR INCREASES SUSTAINED VIROLOGICAL RESPONSE (SVR) RATES IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION
    Desai, Mitesh
    SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 (05) : 449 - 449
  • [5] VIROLOGIC RESPONSE TO AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, WITH AND WITHOUT RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: WEEK 12 INTERIM RESULTS OF THE SOUND-C2 STUDY
    Zeuzem, Stefan
    Soriano, Vincent
    Asselah, Tarik
    Bronowicki, Jean-Pierre
    Ceausu, Emanoil
    Lohse, Ansgar W.
    Streinu-Cercel, Adrian
    Preotescu, Liliana
    Moussalli, Joseph
    Mullhaupt, Beat
    Schuchmann, Marcus
    Bourliere, Marc
    Calinas, Filipe
    Buti, Maria
    Roberts, Stuart K.
    Gane, Edward J.
    Stern, Jerry O.
    Nehmiz, Gerhard
    Bonaventura, Helge
    Boecher, Wulf O.
    Mensa, Federico J.
    HEPATOLOGY, 2011, 54 : 1436A - 1436A
  • [6] Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and-3 HCV infection: results from a Russian Phase IIIb study
    Isakov, Vasily
    Zhdanov, Konstantin
    Kersey, Kathryn
    Svarovskaia, Evguenia
    Massetto, Benedetta
    Zhu, Yanni
    Knox, Steven J.
    Bakulin, Igor
    Chulanov, Vladimir
    ANTIVIRAL THERAPY, 2016, 21 (08) : 671 - 678
  • [7] SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
    Sulkowski, M. S.
    Ceasu, E.
    Asselah, T.
    Caruntu, F. A.
    Lalezari, J.
    Ferenci, P.
    Streinu-Cercel, A.
    Fainboim, H.
    Tanno, H.
    Preotescu, L.
    Leggett, B.
    Bessone, F.
    Mauss, S.
    Stern, J. O.
    Haefner, C.
    Datsenko, Y.
    Nehmiz, G.
    Boecher, W.
    Steinmann, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S27 - S27
  • [8] EFFICACY AND SAFETY OF TMC435 IN COMBINATION WITH PEGINTERFERON α-2A AND RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 HCV PATIENTS: 24-WEEK INTERIM RESULTS FROM THE PILLAR STUDY
    Fried, Michael W.
    Buti, Maria
    Dore, Gregory J.
    Ferenci, Peter
    Jacobson, Ira
    Marcellin, Patrick
    Zeuzem, Stefan
    Lenz, Oliver
    Peeters, Monika
    Sekar, Vanitha J.
    De Smedt, Goedele
    HEPATOLOGY, 2010, 52 (04) : 403A - 404A
  • [9] HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C
    Kwo, P.
    Lawitz, E.
    McCone, J.
    Schiff, E.
    Vierling, J.
    Pound, D.
    Davis, M.
    Galati, J.
    Gordon, S.
    Ravendhran, N.
    Rossaro, L.
    Anderson, F.
    Jacobson, I.
    Rubin, R.
    Koury, K.
    Brass, C.
    Chaudhri, E.
    Albrecht, J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S4 - S4
  • [10] PREDICTION OF SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH TELAPREVIR PLUS PEGYLATED INTERFERON AND RIBAVIRIN IN PHASE 3 TRIALS
    Zeuzem, S.
    Demasi, R.
    Foster, G. R.
    Buti, M.
    Baldini, A.
    Luo, D.
    Witek, J.
    Rizzetto, M.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S452 - S452
12345